Nortriptyline

Speaker 1...and this brings us to nortriptyline. It’s a tricyclic antidepressant often used for pain, particularly neuropathic pain. While it can offer significant relief, we need to look at the evidence regarding its long-term effects on aging and mortality.

Speaker 2Exactly. The benefit of pain relief is crucial, as chronic pain itself can accelerate biological aging. We see this, for instance, in a study in *GeroScience* from 2025, showing painful diabetic neuropathy is linked to accelerated epigenetic aging and telomere shortening.

Speaker 1So, treating pain is vital. However, nortriptyline belongs to a class of drugs with anticholinergic properties. And a large study in *JAMA Internal Medicine* from 2015 found a significant association between higher cumulative anticholinergic use and an increased risk for dementia, with tricyclic antidepressants being a commonly used class.

Speaker 2That's a serious consideration. While nortriptyline might have fewer anticholinergic side effects than some other TCAs, the cumulative impact is still relevant. The challenge is balancing the proven benefit of pain relief against potential long-term cognitive risks.

Speaker 1And what's still unknown? We've got evidence linking anticholinergics to dementia risk, and chronic pain to accelerated aging, but direct, long-term studies specifically on nortriptyline's effect on biological aging markers or all-cause mortality are less clear.

Speaker 2Right. We don't have definitive evidence showing nortriptyline *directly* accelerates epigenetic aging or impacts all-cause mortality in the same way we see the dementia link. It's a complex picture requiring careful individual consideration with a healthcare provider.